



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/884,098	06/20/2001	Kenneth S. Koeneman	9426-022-999

**CONFIRMATION NO. 2402**

20582  
PENNIE & EDMONDS LLP  
1667 K STREET NW  
SUITE 1000  
WASHINGTON, DC 20006

**FORMALITIES LETTER**



\*OC000000009361989\*

Date Mailed: 01/10/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*RL*

---

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



03-11-03

0360

Express Mail No.: EL 401 280 679 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Koeneman *et al.*

Application No.: 09/884,098

Group Art Unit: 1636

Filed: June 20, 2001

Examiner: To be assigned

For: BONE SIALOPROTEIN BASED  
TOXIC GENE THERAPY FOR THE  
TREATMENT OF CALCIFIED  
TUMORS AND TISSUES

Attorney Docket No.: 9426-022

Confirmation No.: 2402

**AMENDMENT FEE TRANSMITTAL SHEET**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, Virginia 22202

Sir:

The fee required to be filed with the accompanying Preliminary Amendment under 37 C.F.R. § 1.115 of even date herewith concerning the above-identified application has been estimated to be \$-0-.

Please charge any required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date March 7, 2003

Geraldine F. Baldwin 31,232  
Geraldine F. Baldwin (Reg. No.)

By:

William Thomann 40,203  
William Thomann (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090



#7

Express Mail No.: EL 401 280 679 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Koeneman *et al.*

Application No.: 09/884,098

Group Art Unit: 1636

Filed: June 20, 2001

Examiner: To be assigned

For: BONE SIALOPROTEIN BASED  
TOXIC GENE THERAPY FOR THE  
TREATMENT OF CALCIFIED  
TUMORS AND TISSUES

Attorney Docket No.: 9426-022

Confirmation No.: 2402

**TRANSMITTAL OF SEQUENCE LISTING**

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, Virginia 22202

Sir:

In response to the Notice to Comply with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 10, 2003, Applicants submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c), (d) and (e), respectively.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c), (d) and (e), respectively, are the same. I hereby state that the submission herein under 37C.F.R. §1.821(g) does not include new matter.

Respectfully submitted,

Date: March 7, 2003

Geraldine F. Baldwin 31,232  
Geraldine F. Baldwin (Reg. No.)

By: William Thomann 40,203  
William Thomann (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090